TEXAS RETINA ASSOCIATES

EyePoint Pharmaceuticals has dosed the first patient in the Phase 3 LUGANO trial of Duravyu (EYP-1901) for wet AMD. Duravyu is a sustained delivery therapy using vorolanib, a selective tyrosine kinase inhibitor. The global, randomized, double-masked Phase 3 trials (LUGANO and LUCIA) aim to enroll 400 patients each, comparing Duravyu to aflibercept. Duravyu, administered every six months, could potentially revolutionize treatment by reducing the need for frequent injections.